The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease
Abstract
OBJECTIVE— PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) enrolled patients with type 2 diabetes and preexisting cardiovascular disease. These patients were at high risk for heart failure, so any therapeutic benefit could potentially be offset by risk of associated heart failure mortality. We analyzed the heart failure cases to assess the effects of treatment on morbidity and mortality after reports of serious heart failure. RESEARCH DESIGN AND METHODS— PROactive was an outcome study in 5,238 patients randomized to pioglitazone or placebo. Patients with New York Heart Association Class II–IV heart failure at screening were excluded. A serious adverse event of heart failure was defined as heart failure that required hospitalization or prolonged a hospitalization stay, was fatal or life threatening, or resulted in persistent significant disability or incapacity. Heart failure risk was evaluated by multivariate regression. RESULTS— More pioglitazone (5.7%) than placebo patients (4.1%) had a serious heart failure event during the study (P = 0.007). However, mortality due to heart failure was similar (25 of 2,605 [0.96%] for pioglitazone vs. 22 of 2,633 [0.84%] for placebo; P = 0.639). Among patients with a serious heart failure event, subsequent all-cause mortality was proportionately lower with pioglitazone (40 of 149 [26.8%] vs. 37 of 108 [34.3%] with placebo; P = 0.1338). Proportionately fewer pioglitazone patients with serious heart failure went on to have an event in the primary (47.7% with pioglitazone vs. 57.4% with placebo; P = 0.0593) or main secondary end point (34.9% with pioglitazone vs. 47.2% with placebo; P = 0.025). CONCLUSIONS— Although the incidence of serious heart failure was increased with pioglitazone versus placebo in the total PROactive population of patients with type 2 diabetes and macrovascular disease, subsequent mortality or morbidity was not increased in patients with serious heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Self-citationNesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 829
Glycemic Control and Heart Failure Among Adult Patients With Diabetes
Iribarren, C., Karter, A. J., Go, A. S., Ferrara, A., Liu, J. Y., Sidney, S., & Selby, J. V. (2001) · Circulation · doi:10.1161/01.cir.103.22.2668 · Cited by 710
Congestive Heart Failure in Type 2 Diabetes
Nichols, G. A., Hillier, T. A., Erbey, J. R., & Brown, J. B. (2001) · Diabetes Care · doi:10.2337/diacare.24.9.1614 · Cited by 600
Heart failure prevalence, incidence, and mortality in the elderly with diabetes
Bertoni, A. G., Hundley, W. G., Massing, M. W., Bonds, D. E., Burke, G. L., & Goff, D. C. (2004) · Diabetes Care · doi:10.2337/diacare.27.3.699 · Cited by 596
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure
Eurich, D. T., Majumdar, S. R., McAlister, F. A., Tsuyuki, R. T., & Johnson, J. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2345 · Cited by 419
Thiazolidinediones in Type 2 Diabetes Mellitus: Current Clinical Evidence
Diamant, M., & Heine, R. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00004 · Cited by 277
Correlation between cardiovascular disease and diabetes mellitus: current concepts
Nesto, R. W. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.10.016 · Cited by 231
Influence of diabetes mellitus on heart failure risk and outcome
Bauters, C., Lamblin, N., Mc Fadden, E. P., Van Belle, E., Millaire, A., & de Groote, P. (2003) · Cardiovascular Diabetology · doi:10.1186/1475-2840-2-1 · Cited by 216
Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes
Delea, T. E., Edelsberg, J. S., Hagiwara, M., Oster, G., & Phillips, L. S. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.2983 · Cited by 216
Smooke, S., Horwich, T. B., & Fonarow, G. C. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.005 · Cited by 196
The PROactive study: some answers, many questions
Yki‐Järvinen, H. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67504-6 · Cited by 141
Thiazolidinedione-Associated Congestive Heart Failure and Pulmonary Edema
Kermani, A., & Garg, A. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.9.1088 · Cited by 112
Hong, G., Lockhart, A., Davis, B., Rahmoune, H., Baker, S. F., Liang, Y. S., Thompson, P., Shou, Y., O’Shaughnessy, K. M., Ronco, P. M., et al. (2003) · The FASEB Journal · doi:10.1096/fj.03-0181fje · Cited by 110
Leahy, J. L., & Kennedy, L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70034-9 · Cited by 100
Pioglitazone initiation and subsequent hospitalization for congestive heart failure
Karter, A., Ahmed, A., Liu, J., Moffet, H. M., & Parker, M. M. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01704.x · Cited by 91
Adjudication of serious heart failure in patients from PROactive
Rydén, L., Thráinsdóttir, I., & Swedberg, K. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60106-8 · Cited by 41
Irons, B. K., Greene, R. S., Mazzolini, T. A., Edwards, K. L., & Sleeper, R. B. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.2.168 · Cited by 36
Holman, R. R., Retnakaran, R. R., Farmer, A. A., & Stevens, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67914-2 · Cited by 30
Holman, R. R., Retnakaran, R. R., Farmer, A. W., & Stevens, R. H. (2006) · The Lancet · Cited by 28
Guillausseau, P.-J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67911-7 · Cited by 8
Cited by
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
Metadata
- Authors
- Erdmann, E., Charbonnel, B., Wilcox, R. G., Skene, A. M., Massi-Benedetti, M., Yates, J., Tan, M., Spanheimer, R., Standl, E., Dormandy, J. A., & On behalf of the PROactive investigators
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-11-01
- Volume
- 30
- Issue
- 11
- Pages
- 2773-2778
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2135729475
- Cited by
- 290
- References
- 24
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.